ArticleJAC-antimicrobial resistance2026
MYcology Stewardship Tool (MyST): a retrospective, descriptive multidisciplinary team review of antifungal prescribing practice in a UK tertiary centre.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antifungal stewardship (AFS) is essential to managing antimicrobial resistance (AMR), yet remains less well established than antibacterial stewardship. This project aimed to support development of an AFS programme at Oxford University Hospitals NHS Foundation Trust (OUHFT) by characterizing antifungal use and identifying priorities for service improvement. Methods: This retrospective service evaluation reviewed all adult patients prescribed systemic antifungal therapy between 1 November 2021 and 28 February 2022. Data were collected using the MYcology Stewardship Tool (MyST) and included patient demographics, underlying diagnosis, fungal infection investigations, antifungal indication, prescribing details and reason for stopping treatment. Guideline compliance and stewardship appropriateness were reviewed independently by two pharmacists. Categorical variables were summarized using counts and percentages, and continuous variables using medians and interquartile ranges. Results were reviewed at fortnightly AFS project team meetings to identify opportunities for service improvement. Results: Two hundred patients, comprising 210 patient episodes, were captured in MyST. Median age was 65 years (IQR 56-73), and 61.5% (123/200) were haematology/oncology patients. Among 140 antifungal prophylaxis prescriptions, 91% (128/140) were guideline compliant and 87% (122/140) were stewardship appropriate. Incorrect duration and poor documentation were the main reasons for inappropriateness. Among 165 antifungal treatment prescriptions, 84% (138/165) were guideline compliant and 85% (140/165) were stewardship appropriate. Incorrect dose or dosing frequency were the main reasons for inappropriateness. AFS project team review identified priority areas for improvement, including staff education, patient information resources and improved therapeutic drug monitoring guidance for complex patients. Conclusion: This project established the foundations for an AFS strategy at OUHFT and identified priorities for further development, including patient information resources, healthcare worker education and therapeutic drug monitoring guidance. Although MyST supported structured data capture and analysis, its use was labour intensive. A dashboard integrated with electronic patient records and capable of providing real-time antifungal prescribing data would facilitate more sustainable, timely and targeted stewardship interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.